Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (Nasdaq: QSI) announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance its core technologies using NVIDIA AI and accelerated computing. The partnership aims to enhance data processing speeds to handle increased data volume from Proteus. By combining NVIDIA's computing capabilities with Quantum-Si's single-molecule protein sequencing technologies, they plan to develop a robust data processing system for generating protein insights to advance research, drug discovery, and healthcare AI. The company is already utilizing NVIDIA BioNeMo for protein structure prediction tools.
Quantum-Si (QSI) and SkyWater Technology are expanding their collaboration to develop the consumable for Proteus™, QSI's next-generation protein sequencing platform. This builds upon their existing partnership since 2021 on the first-generation Platinum® platform. SkyWater will continue supplying consumables for Platinum Pro while supporting Proteus commercialization. The new platform aims to enable simultaneous large factor protein sequencing with enhanced accuracy. SkyWater, certified to ISO 13485 Quality Standard for Medical Devices, will leverage its Technology as a Service (TaaS) model and manufacturing capabilities to support this development.
Quantum-Si (Nasdaq: QSI) has announced a partnership with Planet Innovation for the development and manufacturing of its novel proteomics platform, Proteus™. Planet Innovation, which currently manufactures QSI's Platinum® Pro instrument, will expand its role to support Proteus instrument development and serve as the contract manufacturing partner. The partnership aims to bring the platform to market in under two years, with Planet Innovation leveraging its team of over 400 experts in scientific instrumentation and medical devices development. The Platinum® Pro instrument is scheduled to debut in the first half of 2025.
Quantum-Si (Nasdaq: QSI) announced that its Board's Compensation Committee has granted 340,460 restricted stock units (RSUs) to a new employee under the 2023 Inducement Plan. The RSUs will vest 25% on December 20, 2025, with the remaining vesting in 12 equal quarterly installments thereafter, subject to continued employment. The grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for new employees who were not previously with the company.
Quantum-Si (Nasdaq: QSI) has been awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award in North America for its groundbreaking Platinum® instrument, the first benchtop sequencer offering single-molecule protein sequencing at the amino acid level. The technology enables deep insights into protein structure and function through a compact, accessible, and cost-effective instrument. The Platinum device integrates proprietary image sensors for single-molecule detection and precision sequencing, making protein research more accessible to labs of all sizes. The company's innovation is backed by an extensive intellectual property portfolio of over 1,000 issued and pending patents.
Quantum-Si (QSI) reported Q3 2024 financial results with revenue of $787,000 and gross margin of 47%. The company experienced sales pipeline acceleration but noted lengthening sales cycles, making it unlikely to achieve the full-year revenue guidance of $3.7-4.2 million. Operating expenses were $28.5 million, with a net loss of $25.3 million. Cash position stands at $196.3 million, providing runway into H2 2026. New library preparation and barcoding kits remain on track for Q4 launch. The company appointed Todd Bennett as CCO, highlighting improved commercial execution despite market challenges.
Quantum-Si (QSI) announced a new preprint publication demonstrating their Platinum single-molecule benchtop sequencer's capabilities in distinguishing proteoform-informative peptides within human tropomyosin genes. The study, led by Dr. Gloria Sheynkman at the University of Virginia School of Medicine, showcases Platinum's ability to achieve single amino acid resolution, differentiating TPM1 and TPM2 paralogous peptides and resolving phosphotyrosine modifications and TPM2 splice variants. The technology demonstrates advantages over traditional mass spectrometry techniques, particularly in detecting sequences with challenging molecular weights.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in two upcoming investment conferences. CEO Jeff Hawkins will engage in fireside chat discussions at the UBS Global Healthcare Conference on November 13th at 8:45 AM PT and the Canaccord Medtech, Diagnostics & Services Forum in New York City on November 21st at 8:00 AM ET. Both events will be available via live and archived webcasts in the 'Investors' section of Quantum-Si's website under Events & Presentations.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced an upcoming Investor & Analyst event scheduled for November 20th, 2024, from 10AM to 12PM EST at the Westin NY Times Square. The event will feature presentations from the company's management team, focusing on their technology roadmap, protein sequencing applications, and expanding commercial opportunities. The event includes a live Q&A session.
While in-person attendance is restricted to invited research analysts and institutional investors, others can participate virtually through the company's investor relations website. The webcast recording will remain accessible for at least 90 days after the event.
Quantum-Si (Nasdaq: QSI) announced its participation in the 2024 American Society of Human Genetics Annual Meeting, where it will present on Next-Generation Protein Sequencing (NGPS) technology. The presentation, titled 'From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si's Next-Generation Protein Sequencing Technology,' will feature Dr. Meredith Carpenter and Dr. Colette Felton from UC Santa Cruz.
The presentation will demonstrate how NGPS technology validates transcriptomics predictions by confirming protein presence, abundance, and modifications. Dr. Felton will discuss using long-read RNA sequencing to detect variants in cancer genes and applying NGPS for protein-level validation. Quantum-Si will be available at booth #465 during ASHG 2024.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
